drugset

drugset / Trial / NCT03199872

RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

NCT03199872 ↗

Phase 1/2 Completed 22 enrolled RhoVac APS Dantrials Aps · collab

NaSingle-groupOpen-labelTreatment

Summary

The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer

Timeline

Start: 2017-03-30
Primary completion: 2018-08-01
Completion: 2019-03-29

Publications

Schuhmacher J, Heidu S, Balchen T, Richardson JR, Schmeltz C, Sonne J, Schweiker J, Rammensee HG, Thor Straten P, Roder MA, Brasso K, Gouttefangeas C. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. J Immunother Cancer. 2020 Nov;8(2):e001157. doi: 10.1136/jitc-2020-001157.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RV001V	Vaccine	0.1 mg	Subcutaneous

Indications